Radiopharmaceutical needed for prostate cancer patient.
Ended Awarded Last action
- Contract number
- HT009026FG0110043
- Awardee
-
Sofie CO. UEI JV1AHJHGUGG3
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $10,826
Award facts
- Contract value 100% obligated
- $10,826.16 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Sterling, VA, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Health Agency awarded Sofie CO. (doing business as IBA Molecular) a $10,826.16 firm fixed-price call under a blanket purchase agreement for radiopharmaceutical supply supporting prostate cancer patient diagnostics. The contract, effective through September 30, 2026, represents a task order for specialized molecular imaging agents to support military medical treatment facilities. This award carries no set-aside designation and reflects Sofie CO.'s established position as a specialized supplier of positron emission tomography (PET) radiopharmaceuticals to the federal healthcare system.
Sofie CO., a Sterling, Virginia-based subsidiary of Sofie Biosciences, Inc., specializes in the development and delivery of diagnostic and therapeutic radiopharmaceuticals for cancer detection and neurological imaging. The company maintains multiple indefinite delivery contracts and blanket purchase agreements valued at over $30 million across the Department of Veterans Affairs and Defense Health Agency, supplying critical PET imaging agents including PYLARIFY (piflufolastat F-18) for prostate cancer detection, FDG-18 for general oncology imaging, and various gallium and copper-based radiopharmaceuticals. This task order aligns with the Defense Health Agency's $6.5 million master blanket purchase agreement for pharmaceutical supplies established in February 2024, facilitating streamlined procurement of essential diagnostic radiopharmaceuticals for military personnel and their families.
Quick answers
Who was awarded contract HT009026FG0110043?
HT009026FG0110043 was awarded to Sofie CO. by Defense Health Agency (Department of Defense) on December 23, 2025.
How much is contract HT009026FG0110043 worth?
The government has obligated $10,826 on HT009026FG0110043.
Is contract HT009026FG0110043 an order under another contract?
Yes. HT009026FG0110043 is a BPA call under HT001424A0002, a blanket purchase agreement.
Was contract HT009026FG0110043 competed?
The extent of competition for HT009026FG0110043 was competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award